Brain Cancer Archives - Page 2 of 3 - NFCR

Brain Cancer

GBM AGILE – Changing the Way We Fight Brain Cancer

GBM survival rates have not improved in any meaningful way in over 30 years despite desperate efforts. Glioblastoma Multiforme, referred to simply as GBM, is the deadliest type of brain cancer. GBM is widely regarded as incurable and universally fatal, killing 95% of patients within five years of diagnosis. It is…...

Read more

Treating Brain Cancer: What You Need to Know

Though the chance of developing brain cancer is quite rare, it is ranked as the tenth leading cause of death for both men and women. Despite being one of the most common cancers amongst children, brain cancer is relatively rare amongst the general population. In fact, the chance that a…...

Read more

A Major Milestone! Global Coalition Launches World’s First Adaptive Clinical Trial Platform for Glioblastoma

Glioblastoma Multiforme (GBM) is the deadliest and most aggressive form of brain cancer for which there is currently no cure. This often-fatal brain cancer accounts for 45% of all malignant brain tumors and 12,000 cancer diagnoses per year in the United States, in addition to tens of thousands more around…...

Read more

Origin Cells of Glioblastoma May Have Been Identified

In what could be a major breakthrough, scientists at the Korea Advanced Institute of Science and Technology (KAIST) in South Korea claim to have identified the cellular origin of glioblastoma, a fast-growing type of central nervous system tumor that forms from supportive tissue of the brain and spinal cord. It…...

Read more

Showing Promise: Confronting Brain Cancer in the Lab

Any brain cancer surgery carries significant risk. For one, post-procedural swelling can be deadly. Doctors must also take into account the size of the tumor, its type and grade, the location and whether or not it is pressing against a vital part of the brain. Moreover, the brain is the…...

Read more

“Pink Drink” to Aid Brain Tumor Treatment

Approved in June 2017 by the U.S. Food and Drug Administration and launched commercially in-country in October 2018, 5-Aminolevulinic Acid (also known as 5-ALA, and composed of aminolevulinic acid hydrochloride) is an optical imaging agent for use in patients with high-grade gliomas. Nicknamed the “pink drink,” 5-ALA is a surgical…...

Read more